ArticleMikrochimica acta2026
Bioinspired catecholamine-derived AuNPs@polynorepinephrine@MWCNT electroactive nanomaterial for real-time monitoring of glucose dynamics.
Article in Mikrochimica acta, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
A bioinspired nanomaterial is introduced based on polynorepinephrine (PNE) grafted to multi-walled carbon nanotubes (MWCNT) with gold nanoparticle decoration (Au NPs), developed as an advanced electroactive interface for glucose biosensing. The nanoplatform was deposited on a screen-printed electrode (SPE) with glucose oxidase (GOx) from Aspergillus niger for potential use in point-of-care testing based on a rapid electrocatalytic response to glucose. This molecular-level modification strategy provides an effective approach to tailor catecholamine-derived polymers and improve their electrochemical performance. This biosensor demonstrated a wide linear range (0.1-30.0 mM), with a limit of detection of 2.15 µM and a limit of quantification of 6.52 µM, and sustained stability up to 20 weeks. The biosensor was used to perform in vitro tests with other analytical devices, including a clinical glucometer and a home glucometer. The repeatability and reproducibility of the biosensor were also tested, as well as the possibility of collection of data on changing levels of blood glucose throughout the day. The results demonstrate that the proposed polynorepinephrine-based biosensor represents a promising alternative electroactive coating to the widely studied polydopamine. From an engineering standpoint, the synthesis is compatible with fabrication of screen-printed electrodes. This platform underscores its suitability for potential decentralized point-of-care testing.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.